loading
Schlusskurs vom Vortag:
$37.53
Offen:
$37.53
24-Stunden-Volumen:
1.98M
Relative Volume:
0.89
Marktkapitalisierung:
$6.93B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-10.17
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
-4.69%
1M Leistung:
-7.02%
6M Leistung:
-9.20%
1J Leistung:
-19.96%
1-Tages-Spanne:
Value
$37.16
$37.80
1-Wochen-Bereich:
Value
$37.16
$39.62
52-Wochen-Spanne:
Value
$29.17
$62.40

Revolution Medicines Inc Stock (RVMD) Company Profile

Name
Firmenname
Revolution Medicines Inc
Name
Telefon
415-766-3638
Name
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Name
Mitarbeiter
616
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
RVMD's Discussions on Twitter

Vergleichen Sie RVMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RVMD
Revolution Medicines Inc
37.22 6.99B 29.52M -567.06M -551.11M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-15 Eingeleitet Goldman Buy
2024-07-16 Bestätigt Needham Buy
2024-07-12 Eingeleitet Barclays Overweight
2024-07-08 Eingeleitet Jefferies Buy
2024-04-12 Bestätigt Needham Buy
2024-04-10 Hochstufung Raymond James Outperform → Strong Buy
2024-03-11 Eingeleitet Piper Sandler Overweight
2024-01-05 Hochstufung BofA Securities Neutral → Buy
2024-01-04 Eingeleitet Wedbush Outperform
2023-11-16 Eingeleitet Raymond James Outperform
2023-02-28 Hochstufung JP Morgan Neutral → Overweight
2022-12-14 Eingeleitet Needham Buy
2022-10-21 Eingeleitet Oppenheimer Outperform
2022-05-20 Eingeleitet BofA Securities Neutral
2022-03-01 Hochstufung Stifel Hold → Buy
2021-09-23 Eingeleitet Stifel Hold
2021-08-12 Herabstufung Goldman Buy → Neutral
2021-05-18 Eingeleitet Goldman Buy
2020-05-21 Eingeleitet H.C. Wainwright Buy
2020-03-09 Eingeleitet Cowen Outperform
2020-03-09 Eingeleitet Guggenheim Buy
2020-03-09 Eingeleitet JP Morgan Neutral
Alle ansehen

Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten

pulisher
01:46 AM

What analysts say about Revolution Medicines Inc. Equity Warrant stockFastest-growing stock picks - PrintWeekIndia

01:46 AM
pulisher
01:04 AM

Revolution Medicines publishes research on RAS G12D inhibitor - Investing.com

01:04 AM
pulisher
Jul 24, 2025

What analysts say about Revolution Medicines Inc. stockAccelerated profit realization - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastHigh-octane financial growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Revolution Medicines Inc. stock priceBreakthrough stock performance - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Is Revolution Medicines Inc. a good long term investmentMarket-leading capital gains - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewswire

Jul 24, 2025
pulisher
Jul 24, 2025

Castle Biosciences, Revolution Medicines get FDA breakthrough statuses - MSN

Jul 24, 2025
pulisher
Jul 24, 2025

Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN

Jul 24, 2025
pulisher
Jul 23, 2025

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewswire

Jul 23, 2025
pulisher
Jul 23, 2025

Revolution Medicines Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Castle Bio, Revolution Medicines get FDA breakthrough statuses - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

FDA grants breakthrough therapy designation to Revolution Medicines’ lung cancer drug - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

How will RVMD's EPS trend in Q1 2025? - AInvest

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Revolution Medicines Inc. Equity Warrant stock pricePhenomenal trading returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

Is Revolution Medicines Inc. Equity Warrant a good long term investmentSky-high profits - Autocar Professional

Jul 20, 2025

Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Kapitalisierung:     |  Volumen (24h):